Ian Davis

Jan 10, 2025 | europeanurology.com | Ian Davis

Platinum Priority – Editorial | Referring to the article published on pp.

May 24, 2024 | urotoday.com | Ian Davis

Read the Full Video TranscriptAlicia Morgans: Hi, I'm so excited to be here today with Professor Ian Davis, who's a professor of medicine at Monash University. Thank you so much for being here with me today, and thank you so much for sharing time with me at APCCC 2024 in Lugano, Switzerland, where you gave a wonderful talk to help us think through the challenges of sequencing. Thank you so much, Ian. Ian Davis: Thanks, Alicia. Always a pleasure to talk to you. Alicia Morgans: Wonderful.

Jan 29, 2024 | europeanurology.com | Kosuke Takemura |Matthew Ernst |J. Connor Wells |Audreylie Lemelin |Renee Maria Saliby |Talal El Zarif | +10 more

AbstractPatients with brain metastases (BrM) from renal cell carcinoma and their outcomes are not well characterized owing to frequent exclusion of this population from clinical trials. We analyzed data for patients with or without BrM using the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). A total of 389/4799 patients (8.1%) had BrM on initiation of systemic therapy.

Jul 18, 2023 | frontiersin.org | Justus Liebig |Rudolf Lucas |Ian Davis |Payaningal R. Somanath

IntroductionAcute respiratory distress syndrome (ARDS) is a life-threatening condition first observed and described in the 1960s as the clinical presentation of acute hypoxemia due to pulmonary gas exchange failure in critically ill adults and children (1). ARDS is a complex syndrome, it cannot currently be diagnosed through laboratory tests, imaging, or any other “gold standard” techniques, and current treatments are based solely on supportive care and mechanical ventilation.